8-K: Celcuity Inc. Reports Increased Spending on Clinical Trials, Secures Funding for Operations into 2026

Celcuity Inc. announced its fourth quarter and full year 2023 financial results, highlighting increased spending on clinical trials and securing funding to support operations into the first half of 2026.

Summary

• Celcuity Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company's operating expenses increased significantly, with total operating expenses reaching $19.7 million for the fourth quarter and $66.2 million for the full year.
• Research and development expenses were the primary driver of this increase, rising to $18.1 million in the fourth quarter and $60.6 million for the full year, largely due to the VIKTORIA-1 Phase 3 trial and the initiation of the CELC-G-201 Phase 1b/2 clinical trial.
• The company's net loss for the fourth quarter was $18.8 million, or $0.65 loss per share, and the full year net loss was $63.8 million, or $2.69 loss per share.
• Celcuity raised $65 million through equity sales and expects its cash, cash equivalents, investments, and available funds under its debt facility to fund operations into the first half of 2026.
• The company dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for metastatic castration resistant prostate cancer.
• Topline data from the PI3KCA wild type patient sub-group in the VIKTORIA-1 trial is expected in the second half of 2024, and preliminary data from the prostate cancer trial is expected in the first half of 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful capital raise and progress in clinical trials, but tempered by increased losses and operating expenses. The company is making progress but is still in a high-risk phase.

Positives

• Celcuity successfully raised $65 million through equity sales, strengthening its balance sheet.
• The company's cash position is expected to fund operations into the first half of 2026.
• The Phase 3 VIKTORIA-1 trial remains on track to report topline data for the PI3KCA wild type patient sub-group in the second half of 2024.
• A Phase 1b/2 trial for metastatic castration resistant prostate cancer has been initiated, with the first patient dosed in February 2024.
• Nonclinical data showed gedatolisib to be significantly more potent than other PI3K/AKT/mTOR inhibitors.
• Eldon Mayer was appointed Chief Commercial Officer, bringing 30 years of biopharmaceutical commercial experience.

Negatives

• Celcuity's operating expenses increased significantly in both the fourth quarter and full year 2023.
• The company's net loss widened in both the fourth quarter and full year 2023 compared to the previous year.
• Research and development expenses were substantially higher due to the ongoing clinical trials.
• Net cash used in operating activities increased to $18.5 million in Q4 2023 and $53.8 million for the full year.

Risks

• The company faces risks associated with clinical trial delays, regulatory approvals, and market acceptance of its products.
• There is a risk of competition from other therapies and tools in the market.
• The company's financial performance is heavily dependent on the success of its clinical trials and the commercialization of gedatolisib.
• Increased operating expenses and net losses could impact the company's financial stability if not managed effectively.

Future Outlook

Celcuity expects its current cash reserves, along with available funds under its debt facility, to fund operational activities into the first half of 2026. The company anticipates topline data from the VIKTORIA-1 trial in the second half of 2024 and preliminary data from the prostate cancer trial in the first half of 2025.

Management Comments

• In 2023, we made significant progress advancing development of gedatolisib while strengthening our balance sheet and adding to our leadership team, said Brian Sullivan, CEO and Co-Founder of Celcuity.
• Our Phase 3 VIKTORIA-1 trial remains on track to report topline data from the PI3KCA wild type patient sub-group in the second half of this year.
• We were also excited to begin development of gedatolisib for patients with metastatic castration resistant prostate cancer this past year.

Industry Context

Celcuity is operating in the competitive biotechnology sector, focusing on targeted therapies for oncology. The development of gedatolisib, a pan-PI3K and mTOR inhibitor, positions the company in a space with other companies developing similar therapies. The company's focus on breast and prostate cancer aligns with significant unmet medical needs in these areas.

Comparison to Industry Standards

• Celcuity's increased R&D spending is typical for a clinical-stage biotech company advancing multiple trials.
• The company's cash runway into the first half of 2026 is a positive sign, indicating financial stability for the near term.
• The reported net losses are consistent with the financial profile of a company in the clinical development phase, where significant investments are made before potential revenue generation.
• The 300-fold potency of gedatolisib compared to other PAM inhibitors, if confirmed in clinical trials, could provide a competitive advantage.
• Companies like Novartis, Roche, and AstraZeneca are also developing PI3K/AKT/mTOR inhibitors, making the competitive landscape challenging.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased losses but encouraged by the successful capital raise and clinical trial progress.
• Employees may be impacted by the company's financial performance and the progress of clinical trials.
• Patients with breast and prostate cancer may benefit from the development of gedatolisib.
• Creditors may be interested in the company's financial stability and ability to repay debts.
• Suppliers may be impacted by the company's spending on research and development.

Next Steps

• Celcuity will continue to enroll patients in the VIKTORIA-1 Phase 3 trial and the Phase 1b/2 trial for metastatic castration resistant prostate cancer.
• The company will report topline data from the PI3KCA wild type patient sub-group in the VIKTORIA-1 trial in the second half of 2024.
• Celcuity will share preliminary data from the prostate cancer trial in the first half of 2025.
• The company will continue to advance the clinical development of gedatolisib and explore its potential in other solid tumor indications.

Key Dates

Keywords

Celcuity, gedatolisib, clinical trials, oncology, PI3K/AKT/mTOR inhibitors, breast cancer, prostate cancer, financial results, biotechnology, VIKTORIA-1, CELC-G-201